Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2014, Article ID 273060, 8 pages
http://dx.doi.org/10.1155/2014/273060
Review Article

Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia

1Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766-1854, USA
2Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766-1854, USA

Received 12 August 2013; Revised 24 November 2013; Accepted 6 December 2013; Published 4 February 2014

Academic Editor: Vicky A. Cameron

Copyright © 2014 Fadi T. Khasawneh and Gollapudi S. Shankar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [23 citations]

The following is the list of published articles that have cited the current article.

  • Scott R. Beach, Christopher M. Celano, Jeff C. Huffman, and Theodore A. Stern, “Psychopharmacology in the Treatment of Patients with Cardiovascular Disease,” Handbook of Psychocardiology, pp. 1–17, 2015. View at Publisher · View at Google Scholar
  • Takashi Nagayama, Minoru Nishida, Masanori Hizue, Yamato Ogino, and Masato Fujiyoshi, “Adverse Drug Reactions for Medicines Newly Approved in Japan from 1999 to 2013: Hypertension and Hypotension,” Basic & Clinical Pharmacology & Toxicology, 2015. View at Publisher · View at Google Scholar
  • André Souza e Silva, Fernanda Emy Inumaru, Rafael Vidor, André Luciano Manoel, Thamy Dos Santos, Ana Carolina Carvalho, and Daisson José Treviso, “Prevalence and profile of patients on antipsychotics in a hospital in southern Brazil,” Scientia Medica, vol. 25, no. 4, 2015. View at Publisher · View at Google Scholar
  • Aline Costa Barcelos, Andreia Mota Trein, Gustavo Santos Sousa, Luciano Fleury Neto, and Leonardo Baldaçara, “Cardiotoxic effects resulting from the interaction between risperidone and thiazide diuretics,” Jornal Brasileiro de Psiquiatria, vol. 63, no. 4, pp. 379–383, 2015. View at Publisher · View at Google Scholar
  • Joyce Wei Xin Chong, Earl Hsien-Jie Tan, Chia Eng Chong, Yiwei Ng, and Ruki Wijesinghe, “Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects,” Mental Health Clinician, vol. 6, no. 4, pp. 178–184, 2016. View at Publisher · View at Google Scholar
  • Mi Li, Zhang Guanghui, Zhipeng Cao, Chang Yuefeng, and Zhu Baoli, “Mechanism of antipsychotic-induced sudden cardiac death and its significance of forensic medicine,” Chinese Journal of Forensic Medicine, vol. 31, no. 3, pp. 264–267, 2016. View at Publisher · View at Google Scholar
  • Scott R. Beach, Christopher M. Celano, Jeff C. Huffman, and Theodore A. Stern, “Psychopharmacology in the Treatment of Patients with Cardiovascular Disease,” Handbook of Psychocardiology, pp. 1043–1059, 2016. View at Publisher · View at Google Scholar
  • Christoffer Polcwiartek, Kristian Kragholm, Ole Schjerning, Claus Graff, and Jimmi Nielsen, “Cardiovascular safety of antipsychotics: a clinical overview,” Expert Opinion On Drug Safety, vol. 15, no. 5, pp. 679–688, 2016. View at Publisher · View at Google Scholar
  • Donna Ames, Sian M. Carr-Lopez, Mary A. Gutierrez, Joseph M. Pierre, Jennifer A. Rosen, Susan Shakib, and Lynn M. Yudofsky, “Detecting and Managing Adverse Effects of Antipsychotic Medications,” Psychiatric Clinics of North America, 2016. View at Publisher · View at Google Scholar
  • Mantana Kittipeerachon, and Warawat Chaichan, “Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial,” Schizophrenia Research, vol. 176, no. 2-3, pp. 231–238, 2016. View at Publisher · View at Google Scholar
  • Adel E. Berbari, Najla A. Daouk, and Abdo R. Jurjus, “Secondary Hypertension: Infrequently Considered Aspects—Illicit/Recreational Substances, Herbal Remedies, and Drug-Associated Hypertension,” Disorders of Blood Pressure Regulation, pp. 723–759, 2017. View at Publisher · View at Google Scholar
  • Andrew McGarry, Karl Kieburtz, Victor Abler, Igor D. Grachev, Sanjay Gandhi, Peggy Auinger, Spyridon Papapetropoulos, and Michael Hayden, “Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington’s Disease,” Journal of Huntington's Disease, pp. 1–11, 2017. View at Publisher · View at Google Scholar
  • Aurélie Delacrétaz, Adna Zdralovic, Frederik Vandenberghe, Nuria Saigi-Morgui, Anaïs Glatard, Lina Quteineh, Mehdi Gholam-Rezaee, Wassim Raffoul, Lee Ann Applegate, Paris Jafari, Franziska Gamma, Armin von Gunten, Philippe Conus, and Chin B. Eap, “Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs,” Gene, 2017. View at Publisher · View at Google Scholar
  • Kehinde Sola Akinlade, Oyejide Afolabi Olaniyan, Victor Olufolahan Lasebikan, and Sheu Kadiri Rahamon, “Vitamin D Levels in Different Severity Groups of Schizophrenia,” Frontiers in Psychiatry, vol. 8, 2017. View at Publisher · View at Google Scholar
  • Zoltán Rihmer, Xénia Gonda, and Péter Döme, “Is mania the hypertension of the mood? Discussion of a hypothesis,” Current Neuropharmacology, vol. 15, no. 3, pp. 424–433, 2017. View at Publisher · View at Google Scholar
  • Gricel Paulina Orellana Vidal, Matías Rodríguez, Nicolás González, and Eduardo Durán, “The association of schizophrenia with chronic non transmissible diseases,” Revista Medica de Chile, vol. 145, no. 8, pp. 1047–1053, 2017. View at Publisher · View at Google Scholar
  • Mario Miniati, Marly Simoncini, Federica Vanelli, Caterina Franceschini, Gabriele Massimetti, Claudia Carmassi, and Liliana Dell’Osso, “QT and QTc in Male Patients with Psychotic Disorders Treated with Atypical Neuroleptics,” The Scientific World Journal, vol. 2017, pp. 1–5, 2017. View at Publisher · View at Google Scholar
  • Santiago G. Lago, and Sabine Bahn, “Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia,” ACS Chemical Neuroscience, 2018. View at Publisher · View at Google Scholar
  • Krithika Rajagopalan, John W. Newcomer, Antony Loebel, and Daisy Ng-Mak, “Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: A US claims database analysis,” BMC Health Services Research, vol. 18, no. 1, 2018. View at Publisher · View at Google Scholar
  • Dina M. Aly El-Gabry, Karim Abdel Aziz, Tarek Okasha, Hanan Azzam, and Ahmed Okasha, “Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia,” Journal of Clinical Psychopharmacology, vol. 38, no. 1, pp. 27–33, 2018. View at Publisher · View at Google Scholar
  • Ösby, Gissler, Prieto, Bobo, Erlinge, Alfredsson, Westman, Eriksson, Hällgren, and Frye, “Increased cardiovascular mortality in people with schizophrenia: A 24-year national register study,” Epidemiology and Psychiatric Sciences, vol. 27, no. 5, pp. 519–527, 2018. View at Publisher · View at Google Scholar
  • Sneha Lopes, Oluchi Abosi, Samantha Schmitz, and Jess G. Fiedorowicz, “Cardiometabolic effects of psychotropic medications,” Hormone Molecular Biology and Clinical Investigation, vol. 36, no. 1, 2018. View at Publisher · View at Google Scholar
  • I. H. Heiberg, B. K. Jacobsen, L. Balteskard, J. G. Bramness, Ø. Næss, E. Ystrom, T. Reichborn‐Kjennerud, C. M. Hultman, R. Nesvåg, and A. Høye, “Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness,” Acta Psychiatrica Scandinavica, 2019. View at Publisher · View at Google Scholar